fluoxetine has been researched along with atenolol in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Caron, G; Ermondi, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Campeas, R; Fallon, BA; Feerick, J; Gitow, A; Hollander, E; Liebowitz, MR; Saoud, JB; Schneier, FR; Street, L; Welkowitz, LA | 1 |
| Connoley, IP; Frost, I; Heal, DJ; Liu, YL; Reckless, IP; Stock, MJ | 1 |
| Chen, LY; Shen, WK | 1 |
| Castañeda, G; De Andrés, F; Ríos, A | 1 |
| Furutani, K; Inanobe, A; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Barceló, D; Kasprzyk-Hordern, B; López-Serna, R; Petrović, M | 1 |
| Budzinski, H; Choubert, JM; Coquery, M; Miège, C; Pomiès, M; Wisniewski, C | 1 |
| Gedde-Dahl, A; Molden, E; Spigset, O | 1 |
2 review(s) available for fluoxetine and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Neurocardiogenic syncope: latest pharmacological therapies.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Fluoxetine; Heart Rate; Humans; Midodrine; Patient Education as Topic; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Syncope, Vasovagal | 2006 |
17 other study(ies) available for fluoxetine and atenolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Treatment of social phobia with drugs other than benzodiazepines.
Topics: Adolescent; Atenolol; Benzamides; Buspirone; Child; Clinical Trials as Topic; Female; Fluoxetine; Humans; Male; Moclobemide; Phenelzine; Phobic Disorders; Placebos | 1991 |
Thermogenic effects of sibutramine and its metabolites.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Atenolol; Body Temperature; Body Temperature Regulation; Chlorisondamine; Cyclobutanes; Dose-Response Relationship, Drug; Female; Fluoxetine; Ganglionic Blockers; Glucose; Oxygen Consumption; Phenethylamines; Propanolamines; Rats; Rats, Wistar | 1999 |
Use of toxicity assays for enantiomeric discrimination of pharmaceutical substances.
Topics: Animals; Atenolol; Chlorophyta; Dihydroxyphenylalanine; Eukaryota; Fluoxetine; Molecular Structure; Stereoisomerism; Toxicity Tests; Toxins, Biological; Water Pollutants, Chemical | 2009 |
Pharmacophore modeling for hERG channel facilitation.
Topics: Animals; Atenolol; Chlorpheniramine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Haloperidol; Humans; Hydrophobic and Hydrophilic Interactions; Imipramine; Metoprolol; Nortriptyline; Potassium Channel Blockers; Promethazine; Propranolol; Quantitative Structure-Activity Relationship; Sotalol; Terfenadine; Verapamil; Xenopus laevis | 2012 |
Multi-residue enantiomeric analysis of pharmaceuticals and their active metabolites in the Guadalquivir River basin (South Spain) by chiral liquid chromatography coupled with tandem mass spectrometry.
Topics: Atenolol; Chromatography, Liquid; Environmental Monitoring; Fluoxetine; Metoprolol; Pharmaceutical Preparations; Propanolamines; Propranolol; Reproducibility of Results; Rivers; Sensitivity and Specificity; Spain; Stereoisomerism; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2013 |
Lab-scale experimental strategy for determining micropollutant partition coefficient and biodegradation constants in activated sludge.
Topics: Aerobiosis; Anaerobiosis; Atenolol; Biodegradation, Environmental; Carbon; Denitrification; Diclofenac; Fluoxetine; Ibuprofen; Nitrification; Sewage; Wastewater; Water Pollutants, Chemical | 2015 |
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Topics: Antidepressive Agents; Atenolol; Bisoprolol; Bupropion; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Fluoxetine; Humans; Metoprolol; Paroxetine; Retrospective Studies | 2022 |